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Abstract
Pancreatic ductal adenocarcinoma (PDAC) represents the most common form of pancre-
atic cancer with rising incidence in developing countries and overall 5-year survival rates of
less than 5%. The most frequent mutations in PDAC are gain-of-function mutations in
KRAS as well as loss-of-function mutations in p53. Both mutations have severe impacts on
the metabolism of tumor cells. Many of these metabolic changes are mediated by transport-
ers or channels that regulate the exchange of metabolites and ions between the intracellular
compartment and the tumor microenvironment. In the study presented here, our goal was to
identify novel transporters or channels that regulate oxidative phosphorylation (OxPhos) in
PDAC in order to characterize novel potential drug targets for the treatment of these can-
cers. We set up a Seahorse Analyzer XF based siRNA screen and identified previously
described as well as novel regulators of OxPhos. The siRNA that resulted in the greatest
change in cellular oxygen consumption was targeting the KCNN4 gene, which encodes for
the Ca2+-sensitive K+ channel KCa3.1. This channel has not previously been reported to reg-
ulate OxPhos. Knock-down experiments as well as the use of a small molecule inhibitor
confirmed its role in regulating oxygen consumption, ATP production and cellular prolifera-
tion. Furthermore, PDAC cell lines sensitive to KCa3.1 inhibition were shown to express the
channel protein in the plasma membrane as well as in the mitochondria. These differences
in the localization of KCa3.1 channels as well as differences in the regulation of cellular
metabolism might offer opportunities for targeted therapy in subsets of PDAC.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) represents the most common form of pancreatic
cancer with increasing incidence in developing countries. It is an aggressive and highly meta-
static cancer with an overall 5-year survival rate of less than 5% [1]. Inactivation of the p53
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tumor suppressor gene and mutationally activated KRAS oncogene are the most common
alterations in PDAC. Mutations in KRAS are present in>90% of PDAC and are the earliest
genetic alterations [2], [3]. The chemotherapeutic gemcitabine is the first-line standard of care
as it was shown to increase the median overall survival from 4.41 to 5.65 months [4], [5]. How-
ever, most clinical trials combining gemcitabine with other targeted therapies have failed or
showed only a minor therapeutic benefit. Therefore, there is an urgent need to identify alterna-
tive drug targets for the treatment of PDAC.
It is widely recognized that cancer cells adapt their metabolic pathways during transforma-
tion to gain a survival advantage [6]. Predominantly, many tumor cells are characterized by
aerobic glycolysis [7], which entails a high rate of glucose uptake and subsequent activity of
glucose transporters (GLUTs) [8], as well as a high excretion rate of lactate, even in the pres-
ence of oxygen [9]. Consequently, many metabolic enzymes and transporters are regulated by
oncogenes and/or tumor suppressor genes. p53 [10] upregulates the expression of GLUTs,
TP53-inducible glycolysis and apoptosis regulator (TIGAR), [11], [12] and mitochondrial res-
piration [13], [14], [15]. In contrast, lack of oxygen or adequate nutrients upregulates p53 [16],
[17], [18]. In PDAC cells KRASmutations [19] were shown to modulate expression of hexoki-
nase 2, which shuttles glucose towards glycolysis and lactate production [20]. Furthermore,
PDAC cells display an increased uptake of glutamine, which is transported to mitochondria
where it is converted to aspartate. Aspartate is transported to the cytosol where it is transami-
nated into oxaloacetate by glutamic-oxaloacetic transaminase 1 (GOT-1) and enters the TCA
cycle to produce reducing equivalents by increasing the NADPH/ NADP+ ratio [21]. Addition-
ally, oncogenic KRAS was shown to increase nuclear factor (erythroid-derived 2)-like 2 (NRF2)
expression which further protects cancer cells from reactive oxygen species (ROS)-induced tox-
icity [22]. Overall, it is evident that the two most common mutations in PDAC, inactivating
p53 and activating KRAS, lead to profound metabolic changes, i.e., increase in glycolysis, gluta-
minolysis, and decrease in mitochondrial activity and oxygen consumption.
Many of the described metabolic pathways depend on transporters to supply the cell with
nutrients such as glucose and amino acids and to export waste products such as lactate [23].
Furthermore, ion channels influence many physiological parameters of the cell, including met-
abolic pathways [24]. Screening approaches directed toward the transportome genes were suc-
cessfully used previously to identify transporters mediating chemoresistance in the panel of
NCI-60 cells and the role of the transportome in tumor angiogenesis was recently reviewed
[25]. Therefore, we aimed to identify novel transporters or channels that regulate the metabo-
lism of pancreatic tumor cells and can be potentially exploited as drug targets for the treatment
of PDAC. For this purpose, we established a Seahorse XF Analyzer based siRNA screen to iden-
tify transporters and/or ion channels regulating OxPhos in the PDAC cell line Mia PaCa-2. In
our screen, we identified the Ca2+-sensitive channel KCa3.1 encoded by the KCNN4 gene as a
novel regulator of oxygen consumption in a subset of PDAC cells, further characterized mito-
chondrial expression of KCa3.1 isoform and observed it to at least partially contribute to the
observed effects on oxygen consumption in these cells.
Materials and Methods
Cell lines and compounds
Panc-1 cells were cultured in DMEM with 10% fetal calf serum; AsPC-1 and BxPC-3 cells were
cultured in RPMI 1640 with 10% fetal calf serum, Capan-1 cells were cultured in IMDM with
20% fetal calf serum; Mia PaCa-2 cells were cultured in DMEM/F12 with 10% fetal calf serum
and 2.5% horse serum; All media used for routine passaging contained GlutaMAX and 25 mM
glucose. KCNN4 inhibitor rac-16 was synthesized as described before [26], NS309 and TRAM-
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34 were obtained from Sigma-Aldrich (St. Louis, MO, USA), diluted in DMSO to 10 mM stock
solutions and stored in -20°C. Oligomycin (Oligo), FCCP (carbonyl cyanide-4 (trifluoro-
methoxy) phenylhydrazone), rotenone (R) and antimycin A (A) were obtained from Sigma-
Aldrich (St. Louis, MO, USA), diluted in DMSO to 10 mM stock solutions and stored in -20°C.
Saponin, TMPD (N,N,N0,N0-tetramethyl-p-phenylenediamine), and sodium ascorbate were
obtained from Sigma-Aldrich, (St. Louis, MO, USA).
Metabolic Flux analysis
For Metabolic Flux analysis the Seahorse XF96 instrument (Seahorse Bioscience, Chicopee,
MA, USA) was used and all the procedures were performed according to manufacturer’s
instructions. Briefly, 25 000 cell/well were seeded the night before performing the assay. Cells
were washed twice with Assay medium containing 11 mM glucose, 2 mM sodium pyruvate
and 2 mM glutamine and pre-incubated for 1 hr in 37°C in a non-CO2 incubator. Assay was
performed with 4 min mixing, followed by 4 min of measurement.
Seahorse siRNA Screen
siRNAs were selected from the Ambion Silencer Select Human Extended Druggable Genome
siRNA library (Life Technologies, Carlsbad, CA, USA) which consisted of pooled siRNAs of 3
differrent sequences per target gene. Hiperfect transfection reagent (Qiagen, Hilden, Germany)
was used according to manufacturer’s manual, briefly, siRNA/Hiperfect complexes were pre-
pared in 10 μl OptiMEM to have a final concentration of 10 nM of siRNA and 0.5 μl Hiperfect
per well. 2000 cells/well of Mia PaCa-2 cells were seeded in 10 μl of growth media into a Sea-
horse microplate, incubated for 4 hrs with transfection particles, and 180 μl of growth media
was added. 6 independent wells per each gene were transfected, 3 wells for siRNA targeting
SLC2A1 (Glut-1), 3 wells for siRNA targeting UCP-2 and 3 wells for siRNA targeting PLK-1 as
well as 6 wells of untransfected controls were included in each screening plate. Transfected
cells were incubated 72 hrs prior to Seahorse Metabolic flux Analysis. Cells were washed two
times with assay medium, 200 μl of assay medium supplied with a 1:1000 dilution of Hoechst
dye (Sigma-Aldrich, St. Louis, MO, USA) and incubated for 1 hr in a non-CO2 incubator. After
the samples were analyzed, the Hoechst stained nuclei were imaged with the ImageXpress1
Micro XLS System and MetaMorph1 software was used to assay the cell number (Molecular
Devices, Sunnyvale, CA, USA).
For the analysis of the screening data, the average oxygen consumption rate (OCR) and
extracellular acidification rate (ECAR) of 4 measurements for 6 wells was taken, the nuclei
count was performed from the images of 8 squares per well and averaged, the average of 6 wells
then was taken for further Cell number adjustments of OCR and ECAR values. Each plate con-
tained si-PLK-1 (Polo-like kinase 1) control of transfection efficiency, 4 pooled si-SLC2A1
(Glut-1) and si-UCP-2 (Mitochondrial uncoupling protein 2) for Metabolic Flux analysis con-
trol, together with scrambled siRNA (Dharmacon, Lafayette, CO, USA) as well as untrans-
fected controls. The results were calculated as relative to the average of the entire 96-well plate
(except controls) to remove any inter-plate bias. Hits were considered if cell-number adjusted
OCR differed more than 10% from the plate average.
Knock-down confirmation on mRNA level after the screening procedure was not performed
due to the fact that most of the samples were fixed in formalin for the subsequent nuclei count.
XF Cell Mito Stress test
The protocol was according to supplier manual (Seahorse Bioscience, Chicopee, MA, USA)
with the following adaptations: 20 000 cell/well were seeded the night before the assay. Cells
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were washed twice with Assay medium containing 11 mM glucose, 2 mM sodium pyruvate
and 2 mM glutamine and pre-incubated for 1 hr in 37°C in a non-CO2 incubator. Metabolic
Flux assay at the Seahorse XF96 instrument was performed with 4 min mixing, followed by 4
min of measurement, after initial baseline measurement cells were treated with rac-16, follow-
ing 4 cycles of recordings, 1 μM of oligomycin final concentration was injected to each well and
after mixing 4 cycles of mixing and recording were performed. 0.5 μM of FCCP final concen-
tration was injected following 4 cycles of measurements of maximal respiration. The mix of
1 μM of antimycin A and 1 μM of rotenone final concentrations was injected finally and 4 mea-
surement cycles were performed.
Oxygen consumption measurement in permeabilized cells
Mannitol and Sucrose (MAS) buffer was prepared fresh in distilled, deionized water containing
70 mM sucrose, 220 mMmannitol, 10 mM KH2PO4, 5 mMMgCl2, 2 mMHEPES and 1 mM
EGTA. The buffer was pH adjusted to 7.2 with 0.1 M KOH and filter-sterilized. Cell permeabi-
lization was performed as described before [27]. Briefly, Mia PaCa-2 cells were seeded, incu-
bated for 48 hrs, shortly before the assay growth media was substituted with MAS buffer and
analyzed by Seahorse XF96 instrument as described. 25 μg/ml Saponin, 0.5 mM TMPD and 2
mM ascorbate were injected after 17 min of 3 baseline measurements, followed by the addition
of 10 μM rac-16 as indicated after 24 min of permeabilized cells respiration measurements. For
respiration measurements of permeabilized si-NT or si-KCNN4 Mia PaCa-2 cells, cells were
transfected as described below. Seahorse measurements were carried out 24h after the second
transfection. 30 000 cell/well were seeded the night before the assay.
Screening confirmation protocol
For Screening hits confirmation experiments 4x105 Mia PaCa-2 cells were seeded in each well
of 6 well plate and reverse-transfected according to Lipofectamine RNAiMAX (Life Technolo-
gies, Carlsbad, CA, USA) protocol, for KCNN4 the following siRNAs were ordered from Dhar-





Cells were split after 2 days for RNA (48 hrs post-transfection) extraction and seeded for re-
transfection with corresponding siRNAs. Protein samples were prepared 5 days post
transfection.
Gene expression analysis
For the gene expression analysis the cells were harvested and processed according to the
NucleoSpin RNAMini (Macherey-Nagel, Düren, Germany) protocol using QiaCube System
(Qiagen, Hilden, Germany) in accordance with the manufacturer’s manual. RNA concentra-
tion was determined using NanoDrop. 1 μg of total RNA was used for cDNA synthesis accord-
ing to Maxima Reverse Transcriptase protocol (Life Technologies, Carlsbad, CA, USA). 20 μl
reactions were incubated in Applied Biosystems Veriti1 96-Well Thermal Cycler for 10 min
at 25°C, 30 min at 50°C, 5 min at 95°C, and then incubated at 4°C.
Real-time PCR was performed using an Applied Biosystems Step-One Real-Time PCR Sys-
tem. The 20 μl PCR included 0.5 μl RT product, 1× TaqMan1 Fast Advanced Master Mix and
1 μl of TaqMan1 Gene Expression Assay (Applied Biosystems, Foster City, CA, USA). Expres-
sion Assay, Life Technologies Ordering information: Assay ID: Cf02696785_m1, Gene Aliases:
KCa3.1 Regulates OxPhos
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KCNN4; Catalog # 4351372 and 1 μl of endogenous control. For the normalization purposes
Human HPRT1 (HGPRT) Endogenous Control (VIC1 ⁄ MGB Probe, Primer Limited)
(Applied Biosystems, Foster City, CA, USA) was used in a multiplexed reaction together with
FAM-labeled KCNN4 probe. The reactions were incubated in a 96-well optical plate at 95°C
for 10 min, followed by 40 cycles of 95°C for 15 sec and 60° for 10 sec. The Ct data was determi-
nate using default threshold settings. The threshold cycle (Ct) is defined as the fractional cycle
number at which the fluorescence passes the fixed threshold.
Western Blot
Anti-KCNN4 (final concentration 1 μg/ml) and anti-β actin (1:5000 dilution) antibody were
obtained from Sigma-Aldrich, St. Louis, MO, USA. Total OXPHOS HumanWB Antibody
Cocktail (final concentration 3 μg/ml) was obtained from Abcam, Cambridge, UK; IRDye1
800CW Goat anti-Rabbit IgG (H + L), IRDye1 800CW Goat anti-Mouse IgG2a were obtained
from LI-COR Biosciences Lincoln, NE, USA. Secondary antibodies were used at 0.2 μg/ml final
concentration.
Briefly, cells were harvested in RIPA buffer (Life Technologies, Carlsbad, CA, USA) sup-
plied with protease inhibitors, complete Mini EDTA-free (Roche Life Sciences, Indianapolis,
IN, USA) and phosphatase inhibitors PhosphoSTOP (Roche Life Sciences, Indianapolis, IN
USA). Lysate was centrifuged for 15 min at 4°C, protein concentration was determined by a
BCA Protein Assay (Life Technologies, Carlsbad, CA, USA). Protein samples were reduced
and denaturated in 4X NuPAGE1 LDS Sample Buffer and 10X NuPAGE1 Sample Reducing
Agent (Life Technologies, Carlsbad, CA, USA) by incubating for 5 min at 80°C. Proteins were
separated on 4–12% Bis-Tris NuPAGE gels and dry-transferred to nitrocellulose membranes
and blocked in 5% non-fat milk-TBST. The membranes were incubated with antibodies at 4°C
overnight and after thorough washing, the membranes were incubated with the corresponding
secondary antibody for 1 hr. Finally, the membranes were thoroughly washed and subjected to
imaging by ODYSSEY1 CLx (LI-COR Biosciences, Lincoln, NE, USA).
Mitochondria Isolation
The Mitochondria Isolation Kit for Cultured Cells (Life Technologies, Carlsbad, CA, USA) was
used to isolate mitochondria according to manufacturer’s instructions, the Dounce homogeni-
zation protocol was performed with 60 strokes. The supernatant was taken as the cytosolic frac-
tion. Mitochondrial pellets were resuspended in 1% CHAPS buffer for further Western Blot
processing.
Proliferation assay
Cellular growth kinetics were analyzed using the xCELLigence RTCAMP Station (ACEA Bio-
sciences, San Diego, CA, USA) according to manufacturer’s instructions. For the galactose
treatment, cells were resuspended in galactose media and seeded in xCELLigence plates. Rac-
16 treatment was performed as indicated and added to the cells 48 hrs after seeding in glucose
or galactose-containing media. The slope of the exponential phase of the growth curve was cal-
culated in the complementary software. The Relative Growth (%) was calculated as the ratio
between the slope of DMSO-treated cells and the rac-16-treated cells in the appropriate media.
Cell viabilty assay
Cells were seeded in triplicates in 96-well plates at a density of 2000 cells/well. 72 hours after
the second siRNA transfection cell viability was measured using CellTiter-Glo (CTG, Promega)
KCa3.1 Regulates OxPhos
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according to the manufacturer´s protocol. Luminescence was detected in a microplate reader
(Tecan) after 15 min of incubation.
Electrophysiology
Whole-cell patch-clamp recordings were performed using the Axopatch 200B amplifier inter-
faced to a Digidata 1440A controlled by pClamp10 software (Molecular Devices, Sunnyvale,
CA, USA). Analog signals were acquired at 2.5 kHz and filtered at 1 kHz. Glass electrodes were
prepared from borosilicate glass and had an input resistance of 2–6 MO when filled with pipet
solution contained (in millimolar): 140 K-Aspartate, 8 Na-Aspartate, 4.3 CaCl2, 2.06 MgCl2, 5
K-EGTA, 10 HEPES, pH 7.2, free Ca2+ was 1 μM, calculated by MaxChelator software (Stan-
ford University). TRAM-34 concentration was 1 μM. The standard bath solution contained (in
millimolar): 150 Na-Aspartate, 5 KCl, 2 CaCl2, 1 MgCl2, 10 Glucose, 10 HEPES, pH7.4. All
recordings were performed at room temperature (20°C).
ATP production measurement
Mia PaCa-2 cells were incubated in DMEM with 25 mM galactose overnight, followed by com-
pound treatment for 4 hrs. Finally, cells were subjected to ATP measurement using CellTiter
Glo assay (Promega, Madison, WI, USA) according to manufacturer’s instructions. 1 μM of
Oligomycin (Sigma-Aldrich, St. Louis, MO, USA) was used as positive control.
CellTiter Blue assay
Mia PaCa-2 cells were seeded in a Corning 96 well tissue culture plate washed 2 times with PBS
containing Ca2+/Mg2+ and incubated for 2 hrs in the Assay media supplied with different car-
bon sources as described. CellTiter-Blue Cell Viability Assay (Promega, Madison, WI, USA)
was used according to the manufacturer’s instructions.
Statistical analysis
All the samples contained at least 6 replicates. Statistical analysis was performed using Graph-
Pad Prism software version 6.0 (GraphPad Software, La Jolla, CA, USA) for ANOVA test. Sta-
tistical significance is indicated ns–not significant, p-value is>0.05,  for p< 0.05 and  for
p<0.01; Standard Deviation was calculated in Microsoft Excel. When comparing different con-
ditions or expression in the panel of cell lines, ANOVA Tukey test was used and the datasets
were considered significantly different when p<0.05. For the effects of siRNA or compound
treatments ANOVA test with Bonferroni post-hoc and Dunnett’s two-tailed t-test was used as
described in the figure legends.
Results
Screening conditions for the identification of novel metabolic regulators
Five different PDAC cell lines were characterized for the metabolic phenotype by measuring
oxygen consumption rate (OCR) (Fig 1A) and extracellular acidification rate (ECAR) as an
indicator of glycolysis, respectively, (Fig 1B) using the Seahorse XF Analyzer. OCR is an indica-
tor of mitochondrial respiration, and ECAR (proton excretion) is largely the result of glycolysis
(http://www.seahorsebio.com/). All five cell lines showed different metabolic characteristics
with Panc-1 cells being metabolically most active, as indicated by high ECAR and OCR. AsPC-
1 cells were characterized by a low glycolytic rate, whereas BxPC-3 and Mia PaCa-2 cells were
the most glycolytic (Fig 1C and 1D). As pancreatic tumors are known to be rather glycolytic,
we selected Mia PaCa-2 cells for further establishment of optimal conditions for a siRNA-
KCa3.1 Regulates OxPhos
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based screening approach to identify novel carrier or channel proteins that influence OxPhos,
to optimize transfection conditions as well as optimal assay conditions in the Seahorse XF
Analyzer.
The influence of different carbon sources on cellular metabolism was also determined [28].
As expected, replacing glucose with galactose led to a switch from glycolysis to OxPhos, as indi-
cated by elevated oxygen consumption (Fig 2A). Replacing glucose by 2 mM glutamine led to
an increased rate of oxygen consumption attributable to the glutaminolysis, addition of 2 mM
pyruvate or glucose did not significantly increase respiration, Addition of either pyruvate or
glutamine to glucose increased respiration to equal extent.[29]. The highest OCR was observed
by combining all three carbon sources that feed into the TCA cycle and thereby fuel respira-
tion, therefore we determined the optimal screening conditions to be 10 mM glucose, 2 mM
glutamine and 2 mM pyruvate (Fig 2B). For screening purposes, cell number titration experi-
ments were pursued to determine the optimal cell number that allowed efficient transfection as
well as determination of oxygen consumption rate. Titration of the cell number revealed a min-
imum of 5000 tumor cells per well to reliably detect OCR independent of the carbon source
Fig 1. Metabolism of PDAC cell lines. (A)Measurement of OCR, (B) ECAR, (C)OCR/ECAR and (D)metabolic phenotyping were
performed in Seahorse assay medium supplied with 11 mMGlucose, 2 mM Pyruvate and 2 mMGlutamine. 20 000 cells/well were seeded
one day prior to the experiment. n = 12 for each cell line. Tukey’s Multiple Comparison ANOVA test was performed. All groups are
significantly different unless indicated otherwise.
doi:10.1371/journal.pone.0160658.g001
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(Fig 2C). Changes in oxygen consumption were normalized to cell number. Determining the
cell number by counting Hoechst stained nuclei allowed detection of changes independent of
the metabolic phenotype (Fig 2D and 2E).
To identify novel carrier or channel proteins regulating mitochondrial metabolism in
PDAC cell lines, genes were selected based on gene ontologies (GO) associated with transport
or carrier. 18 GOs were selected which led to the identification of 786 putative transporters or
carriers. To determine which of these genes are expressed in Mia PaCa-2 cells, we utilized in-
house microarray gene expression data based on the analysis of 14 biological replicates with
Fig 2. Optimization of screening conditions in Mia PaCa-2 cells. (A)Oxygen consumption measurements (OCR) of Mia PaCa-2 cells in 25mM glucose or
25mM galactose. The Complex I inhibitor rotenone (1 μM) was used as a positive control for the inhibition of OxPhos, n = 6; (B)Measurement of OCR in
media supplied with different carbon sources: 25 mMGlucose, 2 mMGlutamine, 2 mM Na Pyruvate, n = 12; (C) CellTiter Blue fluorescence measurements of
cell titrations cultured in different assay media for 2 hrs, n = 12; (D)OCRmeasurements of Mia PaCa-2 cell titrations in different assay media, n = 12; (E)
Nuclei number count using Hoechst stain in Seahorse plate, n = 12. For A, t-test was performed, *, p-value is 0.01 to 0.05; **, p-value is 0.001 to 0.01; B,
Tukey’s Multiple Comparison ANOVA Test was performed. Groups are significantly different unless indicated otherwise. For C and D, two-tailed t-test was
performed, ns, not significant, p>0.05, *, p-value is 0.01 to 0.05; **, p-value is < 0.01.
doi:10.1371/journal.pone.0160658.g002
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Affymetrix Gene expression arrays. We used the Affymetrix detection call to determine if a
gene was expressed. The fraction of samples with a positive Affymetrix detection call was aver-
aged across all probe sets of a gene, and the gene was considered to be expressed if this value
exceeded 0.4. All the transportome genes identified as being expressed in Mia PaCa-2 cells
were compared with the available Ambion Silencer Select Human Extended Druggable
Genome siRNA library which led to the identification 223 transportome genes (S1 Table).
KCa3.1 channels regulate oxygen consumption specifically in a subset of
pancreatic tumor cell lines
The siRNA based metabolic screening approach of 223 transportome genes in Mia PaCa-2
cells maintained in 10 mM glucose, 2 mM glutamine and 2 mM pyruvate led to the identifica-
tion of 13 hits with an inhibition of cell number adjusted OCR 10% (Table 1) and 15 hits
with an increase of cell number adjusted OCR 10% (Table 2). These included known regula-
tors of metabolism, such as SLC2A3, SLC2A1 and BSG, as well as novel regulators previously
not associated with tumor cell metabolism.
Among these, the KCNN4 gene was the number one hit that decreased cell number adjusted
OCR by more than 20%. In order to confirm KCNN4 as a hit regulating oxygen consumption
in Mia PaCa-2 cells, four independent individual siRNAs were used; three out of four siRNAs
led to a significant decrease of oxygen consumption (Fig 3A). All four siRNAs led to a signifi-
cant reduction of KCa3.1 channel mRNA (Fig 3B, upper panel). However, only siRNA 2, 3 and
4 led to a significant reduction on protein level, which is consistent with their effect on oxygen
consumption (Fig 3B, lower panel). To further confirm the specificity of the OCR reduction,
results were validated using the previously described KCa3.1 channel inhibitor rac-16 [26],
Table 1. Transportome hits which downregulate oxygen consumption >10%.







KCNN43783 22 93 1.00 Intermediate conductance calcium-activated potassium channel protein 4, KCa3.1
SLC26A21836 21 94 1.00 Sulfate transporter.
NEDD4L23327 20 95 1.00 E3 ubiquitin-protein ligase NEDD4-like
SLC19A210560 20 84 1.00 Thiamine transporter 1
PSEN15663 17 72 1.00 Presenilin-1; L-glutamate transport; gamma-secretase complex, an endoprotease
complex that catalyzes the intramembrane cleavage of integral membrane proteins
such as Notch receptors and APP (beta-amyloid precursor protein)
SLC2A14144195 17 94 1.00 GLUT14, GLUT3 duplication. Solute carrier family 2, facilitated glucose transporter
member 14
KCNT2343450 16 96 0.43 Potassium channel subfamily T member 2
SLC25A3281034 16 129 1.00 Mitochondrial folate transporter/carrier; Transports folate across the inner
membranes of mitochondria.
SLC25A123560 15 102 1.00 Tricarboxylate transport protein, mitochondrial. Involved in citrate-H+/malate
exchange. Important for the bioenergetics of hepatic cells as it provides a carbon
source for fatty acid and sterol biosyntheses, and NAD+ for the glycolytic pathway.
SCO29997 13 106 1.00 Acts as a copper chaperone, transporting copper to the Cu(A) site on the cytochrome
c oxidase subunit II (COX2), complex IV assembly
SLC12A26558 12 93 1.00 Basolateral Na-K-Cl symporter
SLC1A46509 11 97 0.93 ASCT1 protein, Neutral amino acid transporter A; Transporter for alanine, serine,
cysteine, and threonine. Exhibits sodium dependence.
BSG682 10 82 1.00 Basigin; Major regulator of SLC16A1, SLC16A3 and SLC16A8 activity
OCR: oxygen consumption rate; CA: cell number adjusted; Cell index: Changes in cell number compared to control transfected cells.
doi:10.1371/journal.pone.0160658.t001
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which resulted in a dose-dependent decrease of OCR in Mia PaCa-2 cells (Fig 3C). This effect
could not be reversed by application of the KCa3.1 channel-specific activator, NS309. Consis-
tently, increasing the extracellular potassium concentration to 60 mmol/l also reduced OCR,
an effect that decreased with increasing compound concentrations, further supporting that
KCa3.1 channel function mediates the observed decrease in OCR (Fig 3C). Interestingly, rac-16
(10 μM) had no effect on OCR of Capan-1, and only minor effects on BxPC-3 cells were
observed. Panc-1 cells were only responsive at the highest concentration of 10 μM. These dif-
ferences in OCR changes upon rac-16 treatment indicate a cell type-specific effect of KCa3.1
channel inhibition on oxygen consumption (Fig 3D–3F).
Corresponding effects were observed on the extracellular acidification rate (ECAR)
(Figure A in S1 File). Inhibition of KCa3.1 channel by rac-16 led to a dose-dependent increase
in ECAR in Mia PaCa-2 cells. Rac-16 had only a weak or no effect on ECAR in the other three
PDAC cell lines.
To further characterize the effect of KCa3.1 channel inhibition, we performed the Seahorse
XFMito Stress test to analyze the influence of rac-16 on maximal expiration (Fig 4). As described
before, adding rac-16 lead to a dose-dependent decrease of basal respiration in MiaPaCa-2 cells.
As expected, the complex V inhibitor oligomycin completely abolished mitochondrial respiration
in the presence or absence of rac-16. Interestingly, after the addition of the uncoupling agent
FCCP, also maximal respiration is strongly inhibited by rac-16 in a dose-dependent manner in
Mia PaCa-2 cells, demonstrating that KCa3.1 channel also regulates respiration under conditions
of mitochondrial stress. Maximal respiration of Panc-1 cells was inhibited only at 10 μM, only
weakly inhibited in BxPC-3 cells and not affected in Capan-1 cells.
Table 2. Transportome hits which upregulate oxygen consumption >10%.







RASA322821 10 106 0.57 Ras GTPase-activating protein 3; calcium-release channel activity
ABCD45826 11 84 1.00 May be involved in intracellular processing of vitamin B12 (cobalamin). Could play a
role in the lysosomal release of vitamin B12 into the cytoplasm.
TAP16890 11 84 0.71 Antigen peptide transporter
TPCN2219931 12 114 1.00 Two pore calcium channel protein 2; Nicotinic acid adenine dinucleotide phosphate
(NAADP) receptor that may function as one of the major voltage-gated Ca2
+ channels (VDCC) across the lysosomal membrane
TNPO13842 13 90 1.00 Transponin, nuclear transport of proteins
SLC25A168034 14 118 1.00 Graves disease autoantigen; Required for the accumulation of coenzyme A in the
mitochondrial matrix
SLC7A823428 15 73 0.64 LAT2, Large neutral amino acids transporter small subunit 2
SLC2A36515 16 97 1.00 GLUT3; Solute carrier family 2, facilitated glucose transporter member 3
SLC25A1310165 17 114 1.00 Calcium-binding mitochondrial carrier protein Aralar2; Catalyzes the calcium-
dependent exchange of cytoplasmic glutamate with mitochondrial aspartate across
the mitochondrial inner membrane. May have a function in the urea cycle.
SLC12A710723 22 127 1.00 Potassium-chloride cotransporter 4
ITGAV3685 23 57 1.00 Integrin 5-alpha
SLC2A16513 27 68 1.00 Glut-1, Solute carrier family 2, facilitated glucose transporter member 1
NUDT953343 28 110 1.00 ADP-ribose pyrophosphatase, mitochondrial
CUL58065 31 108 1.00 Vasopressin-activated calcium-mobilizing receptor 1; p53 regulated,
SLC16A26567 41 99 0.79 MCT8, Monocarboxylate transporter 8. Very active and speciﬁc thyroid hormone
transporter. Stimulates cellular uptake of thyroxine (T4), triiodothyronine (T3), reverse
triiodothyronine (rT3) and diidothyronine. Does not transport Leu, Phe, Trp or Tyr
OCR: oxygen consumption rate; CA: cell number adjusted; Cell index: Changes in cell number compared to control transfected cells.
doi:10.1371/journal.pone.0160658.t002
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To assess the specificity of the observed inhibitor effects, we compared the effect of rac-16
on cells treated with KCa3.1 channel siRNA versus control siRNA (Figure B in S1 File). As
described before, KCa3.1 channel siRNA leads to a significant inhibition of OCR compared to
controls. Subsequent treatment with rac-16 has, most likely due to residual channel expression
after KCa3.1 channel knock-down, smaller effects on KCa3.1 channel siRNA treated cells than
on control cells. The final OCR is comparable between KCa3.1 channel siRNA and control cells
after rac-16 treatment. These results confirm the specificity of the effect of rac-16 on KCa3.1.
KCa3.1 channel inhibition affects OxPhos-dependent cell proliferation
To determine the effect of KCa3.1 channel inhibition on proliferation of PDAC cell lines, Mia
PaCa-2, Panc-1, Capan-1 and BxPC-3 cells were incubated with increasing concentrations of
Fig 3. KCNN4 hit confirmation. (A)OCR of Mia PaCa-2 cells transfected with individual siRNAs against KCNN4, 20 000 cells/well were re-seeded the night
before the assay to avoid cell number-dependent changes. n = 6; (B) Upper panel: KCNN4 TaqMan gene expression assay. KCNN4mRNA levels were
normalized to HPRT. KCa3.1 Lower panel: Western Blot analysis of KCNN4 protein expression,HSP90was used as loading control. Arrow indicates the
KCNN4 protein band. (C)Oxygen consumption measurements of Mia PaCa-2, (D) Panc-1, (E)Capan-1 and (F) BxPC-3 cells treated with rac-16 (KCNN4
inhibitor) at different concentrations as indicated, 100 nM NS309 (KCNN4 activator) and high concentrations of extracellular KCl (60 mM), n = 5. Data are
represented as the mean ± SD. ANOVA test with Bonferroni post-hoc was performed to compare NT siRNA and siRNA targeting KCNN4mRNA; ns, not
significant, p>0.05, *, p-value is 0.01 to 0.05; **, p-value is < 0.01.
doi:10.1371/journal.pone.0160658.g003
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rac-16 (Fig 5A–5D). Replacing 11 mM glucose with 11 mM galactose to shift cellular metabo-
lism towards OxPhos allowed determining effects on OxPhos by measuring cell proliferation.
In all cell lines tested, inhibition of KCa3.1 channel had either no effect on proliferation or simi-
lar, non dose-dependent effects on cell proliferation in the presence of either carbon source.
However, only Mia PaCa-2 cells showed a dose-dependent galactose-specific effect after rac-16
administration. To further confirm these results and the specificity of the inhibitor, Mia PaCa-
2 cells were transfected with three independent siRNAs (si-2, 3 and 4) and replated to assess
cell proliferation. As observed for rac-16, knock-down of KCNN4 by siRNA had no effect on
cell proliferation of Mia PaCa-2 cells in the presence of 11 mM glucose, but led to significantly
reduced cell number in the presence of 11 mM galactose (Fig 5E) 72 hours post-transfection.
This indicates a correlation between the effect of the inhibitor on oxygen consumption and
tumor cell proliferation in galactose.
Mia PaCa-2 cells express a mitochondrial form of KCNN4
KCa3.1 channels are described to be expressed in the plasma membrane as well as in the mito-
chondria [30, 31]. To investigate the underlying mechanisms of KCa3.1 channel mediated
Fig 4. KCa3.1 inhibition modulates oxygen consumption profile in a subset of PDAC cell lines. (A) Seahorse XF Mito Stress test was performed to
measure mitochondrial function upon various concentrations of rac-16 treatment of Mia PaCa-2, (B), Panc-1, (C) BxPC-3, and (D) Capan-1 cells. n = 3. Oligo
is oligomycin A, FCCP is carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone, A/R is a mix of antimycin A and rotenone. n = 6.
doi:10.1371/journal.pone.0160658.g004
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regulation of oxygen consumption, KCa3.1 channel mRNA and protein levels as well as KCa3.1
channel activity was determined. The KCa3.1 channel inhibitor-sensitive cell line Mia PaCa-2
expresses KCa3.1 channel on mRNA and protein level (Fig 6A and 6B). To confirm functional
expression of the channel in the plasma membrane, we performed patch-clamp measurements
in the whole cell configuration and in presence of 1 μM free Ca2+ in pipette solution. Both
BxPC-3 and Mia PaCa-2 cells exhibited current-voltage relationships that revert close to the
calculated reversal potential of K+ (EK
+ = -85 mV), show inward rectification at positive poten-
tial and were sensitive to the KCa3.1 channel -specific inhibitor TRAM-34. All these are charac-
teristics as described for the KCa3.1 channel [32, 33]. These currents were not detected in Panc-
1 cells. (Fig 6C–6E, Figure C in S1 File).
These results show a correlation between the presence of functional KCa3.1 channel in the
plasma membrane and the effect of KCa3.1 channel inhibition on cellular oxygen consumption
and proliferation, indicating a possible role of KCa3.1 channel expressed on the cell surface.
However, KCa3.1 channel was also described to be expressed in the mitochondria and mito-
chondrial expression of the channel indicates an involvement in metabolic processes. There-
fore, the mitochondrial expression of KCa3.1 channel was analyzed in Mia PaCa-2, Panc-1
Capan-1 and BxPC-3 cells. Western Blot analyses of mitochondrial extracts showed highest
KCa3.1 channel protein expression in Mia PaCa-2 cells (Fig 7A). To assess if this mitochondrial
Fig 5. KCa3.1 inhibition affects proliferation. (A) xCELLigence proliferation assay on Mia PaCa-2, (B) Panc-1 (C) Capan-1 and (D) BxPC-3 cells grown in
the presence of 11 mM glucose or galactose as the main energy source and treated with increasing concentrations of rac-16, n = 5 for each condition. The
slope of the exponential phase of the growth curve was calculated in the complementary software. The relative growth was calculated as the ratio between
the slopes of DMSO-and rac-16 treated cells in the appropriate media. (E) Viability assay of Mia PaCa-2 cells transfected with non-targeted siRNA or
individual siRNAs against KCNN4. Assay was conducted 72 hours post-transfection, n = 3. ANOVA Bonferroni test was used to compare each of the rac-16
treatments vs DMSO; ns, not significant, p>0.05,*, p-value is 0.01 to 0.05; **, p-value < 0.01.
doi:10.1371/journal.pone.0160658.g005
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KCa3.1 channel isoform is involved in the regulation of cellular oxygen consumption, metabolic
analyses were performed in permeabilized Mia PaCa-2 cells to exclude the role of cell surface
expressed KCa3.1 channel. Mia Paca-2 cells were transfected with three independent siRNAs
(si-2, 3 and 4) to knock-down KCNN4 and assessed for OCR before and after permeabilization
of the outer cell membrane. As described before, knock-down of KCNN4 led to a significant
decrease of OCR in intact MiaPaCa-2 cells. Permeabilization of the outer membrane induced a
drastic increase in OCR; however, the difference in OCR between KCNN4 knock-down cells
and control transfected cells remained constant before and after permeabilization indicating a
role of the mitochondrial protein in the regulation of OCR (Fig 7B). Furthermore, incubation
of permeabilized cells with 10 μM rac-16 led to a significant decrease in oxygen consumption,
again indicating a role of mitochondrial KCa3.1 channel in the regulation of this process (Fig
7C). Finally, the influence of KCa3.1 channel inhibition on OxPhos-dependent ATP generation
was assessed. Mia PaCa-2 cells were incubated for 4 hours with increasing concentrations of
rac-16 in the presence of galactose as the sole carbon source. Inhibition of KCa3.1 channel by
rac-16 resulted in a 20% decrease in ATP production compared to DMSO-treated control or a
50% depletion of ATP compared to the inhibitor of cellular respiration oligomycin, indicating
Fig 6. KCa3.1 expression and function in the panel of PDAC cell lines. (A) KCNN4 TaqMan gene expression assay, KCNN4mRNA levels were
normalized to HPRT (B) andWestern Blot analysis of KCNN4 protein expression, β-Actin was used as a loading control in PDAC cell lines. Arrow indicates
the KCNN4 protein band (C)Whole-cell patch-clamp recordings in the presence of 1 μM free Ca2+ in pipette solution in Mia PaCa-2, n = 7; (D) BxPC-3,
n = 11; (E) Panc-1 cells, n = 7. TRAM-34 was used as a specific KCa3.1 inhibitor. Tukey’s Multiple Comparison ANOVA Test was performed. p>0.05,*, p-
value is 0.01 to 0.05; **, p-value < 0.01.; for the patch-clamp significance was calculated at the measurement point of KCNN4 current using ANOVA t-test,
ns, not significant, p>0.05, *, p-value is 0.01 to 0.05.
doi:10.1371/journal.pone.0160658.g006
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a role of mitochondrial KCa3.1 channel in the functionality of mitochondrial respiration and
ATP production (Fig 7D).
Discussion
The study presented here aimed to establish an unbiased siRNA screening approach to identify
modulators of OxPhos among ion channels and transporters in PDAC cells. Although the
siRNA-based screen identified many hits that were previously described to regulate metabo-
lism, and thereby confirms the validity of this study, the screen nonetheless has a number of
limitations. One of the major limitations being the lack of cellular heterogeneity present within
Fig 7. MitoKCa3.1 regulatesmitochondrial respiration in Mia PaCa-2 cells. (A)Western Blot analyses of Mia PaCa-2, BxPC-3, Panc-1 and Capan-1
cells; mitochondrial fraction was prepared from equal cell number of each cell line, supernatant frommitochondrial fraction preparation was taken as the
cytosolic fraction. Fractions were compared among each other and to whole cell protein lysates. Antibodies recognizing mitochondrial complex V, III, II, IV
were used as mitochondrial controls and tubulin as the cytosolic control. Arrow indicates the KCNN4 protein band. (B)OCRmeasurement of permeabilized
in Mannitol and Sucrose buffer (MAS) by 25 μg/ml saponin (SAP) Mia PaCa-2 cells transfected with individual siRNAs against KCNN4, 30 000 cells/well were
re-seeded the night before the assay to avoid cell number-dependent changes, n = 4 for each condition, p<0.001. (C)OCRmeasurement of permeabilized in
Mannitol and Sucrose buffer (MAS) by 25 μg/ml saponin (SAP) Mia PaCa-2 cells treated with 10 μMKCa3.1 inhibitor rac-16, n = 32, p<0.01; (D)Mitochondrial
ATP production in Mia PaCa-2 cells upon treatment with varying concentrations of the KCa3.1 inhibitor rac-16 or DMSO, 1 μMOligomycin (Oligo) served as a
positive control, n = 6, p<0.0001. Bonferroni ANOVA test was performed to compare Non-Targeting siRNA vs siRNA targeting KCNN4mRNA or DMSO-vs
rac-16 treatment; ns, not significant, p>0.05, *, p-value is 0.01 to 0.05; **, p-value < 0.01.
doi:10.1371/journal.pone.0160658.g007
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and between different tumors [34], [35], [36], [37]. The screen focused on Mia PaCa-2 cells as
these cells displayed sufficient oxidative capacity to perform the screen and were reliably and
potently transfectable by a wide variety of different siRNAs. The use of additional pancreatic
cancer cell lines or of different tumor entities would allow for the characterization of the meta-
bolic differences between different cancer subtypes. Additionally, most solid tumors have var-
ied niches characterized by differences in the supply of nutrients and oxygen [38]. Low oxygen,
resulting in the upregulation of hypoxia-inducible factors (HIFs), is described to be an impor-
tant regulator of cellular metabolism by inducing the expression of glucose transporters, glyco-
lytic and other metabolic enzymes [39], [40]. Future screens under different environmental
conditions could potentially identify additional regulators of tumor metabolism.
A detailed analysis of screened genes revealed a subset of known modulators of metabolism
which did not appear as regulators of metabolism in the present approach (e.g.,MCT1,
SLC25A10). This could be due to low expression of target mRNAs in Mia PaCa-2 cells, the
presence of compensatory mechanisms, insufficient transfection efficiency, inappropriate tim-
ing for phenotypic readout, or a limited sensitivity of the assay read out. Nevertheless, we were
able to confirm screening hits by using additional individual siRNAs, as well as small molecule
inhibitor and thereby showing the validity of our approach.
We identified several proteins, including KCa3.1 channels as the number one hit, previously
not associated with the regulation of tumor metabolism. We recorded differential functional
expression of KCa3.1 channel in the panel of PDAC cell lines which correlates with a previously
published pattern [41], however does not correlate with the influence of the rac-16 KCa3.1
inhibitor on respiration. Additionally KCa3.1 channel was found to be expressed in the mito-
chondria of these cells. Seahorse Analyzer XF experiments on permeabilized cells show that the
mitochondrial expressed KCa3.1 channel is at least partially responsible for the observed phe-
notype. However, based on our results an additional role of cell surface expressed KCa3.1 chan-
nel on the regulation of cellular oxygen consumption cannot be excluded.
KCa3.1 channels are expressed in erythrocytes, lymphocytes, liver and pancreas as well as in
vascular smooth muscle, endothelial and blood cells [42]. They are important regulators of
vasorelaxation and smooth muscle cell regulation [43], [44]. In addition, KCa3.1 channels were
shown to be expressed in different cancer cell lines and inhibition has been shown to attenuate
neoplastic cell growth both in vitro and in vivo [45], [46], [47], [48]. KCa3.1 channels were
shown to be overexpressed in 32% of glioma patients and the expression correlates with poor
prognosis in both glioma and NSCLC patients [47, 49]. KCa3.1 channels have also been charac-
terized as an important driving force for anion extrusion in normal pancreatic ducts and their
roles in normal physiology, overexpression on PDAC [41], and role in pancreatic pathophysi-
ology were described [50] [51].
Finally, the subcellular localization of KCa3.1 channels was shown to be crucial for the regu-
lation of cell migration [52]. Mitochondrial expression of KCa3.1 channels has been described
previously in HCT116 cells [30]. De Marchi and colleagues found KCa3.1 channels in the inner
mitochondrial membrane where it is regulated by small changes of the mitochondrial matrix
Ca2+ concentration. Here, we describe for the first time a role for KCa3.1 channels in the regula-
tion of oxygen consumption. We were able to confirm mitochondrial expression of KCa3.1
channels in a subset of PDAC cell lines and we suggest that its mitochondrial expression corre-
lates with the regulation of oxygen consumption. Furthermore, we have shown mitochondrial
expressed KCa3.1 channels to be at least partially responsible for the effects of KCa3.1 channels
inhibitor on oxygen consumption. Although a role of mitochondrial expressed KCa3.1 channels
in the regulation of oxygen consumption seems suggestive, we cannot exclude an additional
influence of KCa3.1 channels in the plasma membrane.
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Sassi and colleagues did not observe any influence of mitochondrial KCa3.1 channels on cell
proliferation using TRAM-34 as an inhibitor of KCa3.1 channels [31]. As TRAM-34 is generally
known to have poor solubility and high protein binding, we used the previously described
KCa3.1 channel inhibitor rac-16. Our study confirms the findings of Sassi et al. in the presence
of sufficient glucose. However, forcing cells to generate ATP exclusively via OxPhos using
galactose media sensitizes tumor cells expressing mitochondrial KCa3.1 channels to corre-
sponding inhibitors and reduces proliferation of these cells. The small molecule inhibitor rac-
16 was described to inhibit KCa3.1 channels in a dose-dependent manner with an IC50 of 8 nM
[26]. In contrast, significant higher concentrations of rac-16 are needed to inhibit OxPhos in
Mia PaCa-2 cells. However, the IC50 of rac-16 was originally determined by measuring iono-
mycin-induced Rb+ efflux of preloaded C6BU1 cells and depends very much on channel and
substrate concentrations in the experimental settings. In addition, mitochondrial channels
tend to be less sensitive to inhibitors compared to their plasma-membrane counterparts as a
portion of the drug is likely to be retained in cellular membranes [53]. Off-target effects of rac-
16 cannot be excluded at higher concentrations. However, rac-16 exerts no effects against a
panel of GPCRs and ion channels up to 10μM (data not shown). Finally, different isoforms of
KCNN4 are described to differ in their sensitivity to KCa3.1 channel inhibitors [54]. Therefore,
we can also not exclude the possibility of a specific isoform or modification of the protein that
changes sensitivity towards inhibitors.
The exact mechanisms of KCa3.1 channels mediated control of metabolism and its func-
tional implications have to be elucidated in future studies. However, previous reports have
described a role of potassium ions in the regulation of the mitochondrial membrane potential,
which is a driving force for the respiratory chain [53]. Additionally, K+-flux was described to
regulate mitochondrial volume and as a consequence to regulate respiration. [55] Therefore,
modulating ion concentrations will influence the activity of the respiratory chain and thereby,
ATP production and oxygen consumption.
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S1 File. Figure A. KCNN4 and extracellular acidification. (A) Extracellular Acidification
Rate measurements of Mia PaCa-2, (B) Panc-1, (C) Capan-1 and (D) BxPC-3 cells treated with
rac-16 (KCNN4 inhibitor) at different concentrations as indicated, 100 nM NS309 (KCNN4
activator) and high concentrations of extracellular KCl (60 mM), n = 5. Data are represented as
the mean ± SD. Figure B. KCNN4 hit confirmation.Mia PaCa-2 cells transfected with siRNA
against KCNN4, 20 000 cells/well were re-seeded one the night before the assay, upon 6 base-
line measurements 10 μM of rac-16 or 0.1% DMSO final concentration were injected to the
media, n = 6. Figure C. Differential amplitude of TRAM-34 sensitive current in the panel of
PDAC cell lines. Analyses of the whole-cell patch-clamp recordings in the presence of 1 μM
free Ca2+ in pipette solution at -5.8 mV potential in Mia PaCa-2 (n = 7), BxPC-3 (n = 11) and
Panc-1 cells (n = 7).
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